Poly Medicure has announced the acquisition of 100% stake in Medistream SA (“Group”), consisting of Citieffe SRL and its subsidiaries in USA & Mexico, for EUR 31 Million. Citieffe, an Italy-based manufacturer specializing in orthopaedic trauma and extremities, generated revenues of EUR 17.3 million and EBITDA of EUR 3.1 million in CY 2024. This acquisition provides Poly Medicure an entry into the global orthopaedics market.
Strategic Acquisition of Citieffe Group
Poly Medicure Limited has officially announced the acquisition of Citieffe Group for an enterprise value of EUR 31 Million. This acquisition, announced on September 25, 2025, marks Poly Medicure’s entry into the global orthopaedics market, enhancing its portfolio and global reach.
Deal Highlights
Key details of the transaction include:
- Acquisition of 100% stake in Medistream SA (“Group”) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico.
- Citieffe specializes in the orthopaedic trauma and extremities segment.
- Citieffe has a direct presence in Italy, USA, and Mexico, and distribution across 25+ countries.
- In CY 2024, Citieffe generated revenues of EUR 17.3 million and EBITDA of EUR 3.1 million, reflecting year-on-year growth of 15% and 14% respectively.
Rationale Behind the Acquisition
The acquisition is driven by the following strategic objectives:
- Entry into the large global orthopaedics market, particularly in the trauma and extremities segment.
- Access to a diverse, fully accredited, and patented portfolio of trauma & extremity products with 45 patents.
- Expansion of global presence with direct sales in Italy, USA, and Mexico.
- Synergies through leveraging Polymed’s manufacturing expertise and global distribution network.
Future Plans and Synergies
Post-acquisition, Poly Medicure plans to:
- Expand product portfolio through the addition of Plates.
- Enter the joints replacement market in the medium term.
- Increase US expansion by hiring more sales reps.
- Outsource parts of manufacturing process to India to reduce costs and boost margins.
Management Commentary
Mr. Himanshu Baid, Managing Director, Poly Medicure Limited, stated: “This acquisition marks another step in our journey to become a comprehensive healthcare solutions provider… Together, we will be able to accelerate the expansion into orthopaedics adjacencies and expand reach to more patients globally.”
The acquisition is subject to customary closing conditions and approvals and is expected to close in the next 4-8 weeks.
Source: BSE
